Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
• By Emily Hayes
Full results from the pivotal ARAMIS study of Bayer/Orion's darolutamide were presented at the ASCO GU meeting, held at the George R. Moscone Convention Center in San Francisco Feb. 14-16.
Keep up with the top pharma business news of the week. On the go.
